Molecules, Vol. 25, Pages 1687: Recent Advances in HIV-1 Gag Inhibitor Design and Development

Molecules, Vol. 25, Pages 1687: Recent Advances in HIV-1 Gag Inhibitor Design and Development Molecules doi: 10.3390/molecules25071687 Authors: Alexej Dick Simon Cocklin Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation. However, resistance mutations and the accumulation of severe side effects associated with cART remain enormous challenges that need to be addressed with the continual design and redesign of anti-HIV drugs. In this review, we focus on the importance of the HIV-1 Gag polyprotein as the master coordinator of HIV-1 assembly and maturation and as an emerging drug target. Due to its multiple roles in the HIV-1 life cycle, the individual Gag domains are attractive but also challenging targets for inhibitor design. However, recent encouraging developments in targeting the Gag domains such as the capsid protein with highly potent and potentially long-acting inhibitors, as well as the exploration and successful targeting of challenging HIV-1 proteins such as the matrix protein, have demonstrated the therapeutic viability of this important protein. Such Gag-directed inhibitors have great potential for combating the AIDS pandemic and to be useful tools to dissect HIV-1 biology.
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research